Sandoz Group AG engages in focusing on generic pharmaceuticals and bio similar medical products. The company is headquartered in Rotkreuz, Zug and currently employs 23,406 full-time employees. The company went IPO on 2023-10-04. The firm operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The firm serves customers worldwide.
Sandoz Group AG hisse başına yıllık % {var1} temettüye sahiptir ve % {var2} oranında bir getiri sunmaktadır. Temettü yıllık ödenmektedir ve son temettü hariç tarihi Apr 17, 2025 tarihindedir.
Dividend Yield
Yıllık Dividende
Özsermaye Tarihi
0.00%
$0.73
Apr 17, 2025
Ödeme Sıklığı
Ödeme Oranı
Yıllık
0.00%
Dividend History
Özsermaye Tarihi
Nakit Tutarı
Kayıt Tarihi
Ödeme Tarihi
Apr 17, 2025
$0.60
Apr 22, 2025
Apr 23, 2025
May 3, 2024
$0.45
May 6, 2024
May 7, 2024
Dividend Grafikleri
SDZXF Kâr Payları
SDZXF Dividend Growth (Yıllık Üstünlük)
Follow-Up Questions
Sandoz Group AG'in şu anki temettü ödemesi ve yıllık temettüsü nedir?